Perverse incentives in the medicare prescription drug benefit

Inquiry

Volumn 44, Issue 2, 2007, Pages 157-166

  McAdams, David ^a   Schwarz, Michael ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b YAHOO RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG FORMULARY; DRUG INDUSTRY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; MEDICARE; PRESCRIPTION; PRESCRIPTION DRUG COVERAGE; PROSPECTIVE PAYMENT; PROSPECTIVE PRICING; RISK ASSESSMENT;

EID: 34548251869     PISSN: 00469580     EISSN: None     Source Type: Journal    
DOI: 10.5034/inquiryjrnl_44.2.157     Document Type: Article

References (20)

1. Bendell, J. C., D. Yu, and H. Hurwitz, et al. 2005. Capecitabine and Oxaliplatin (XELOX) in Combination with Bevacizumab in the Treatment of Metastatic Colorectal Cancer: Results of a Phase II Trial. Proceedings from the European Cancer Conference (ECCO 13).
2. Boston Consulting Group (BCG). 2003. Changing Environment for the U.S. Pharmaceuticals. Boston: BCG.
3. Ellis, R. 2001. Formal Risk Adjustment by Private Employers. Inquiry 38(3): 299-309.
4. Feldman, R., B. Dowd, and M. Maciejewski. 2001. A Demand-Side View of Risk Adjustment. Inquiry 38(3): 280-289.
5. Frank, R. 2001. Prescription Drug Prices: Why Do Some Pay More than Others Do? Health Affairs 20(2): 115-128.
6. Frank, R., and M. Rosenthal. 2001. Health Plans and Selection: Formal Risk Adjustment vs. Market Design and Contracts. Inquiry 38(3): 290-298.
7. Glazer, J., and T. McGuire. 2000. Optimal Risk Adjustment in Markets with Adverse Selection: An Application to Managed Care. American Economic Review 90(4): 1055-1071.
8. _. 2001. Private Employers Don't Need Formal Risk Adjustment. Inquiry 38(3): 260-269.
9. Goldman, D., G. Joyce, and J. Escarce, et al. 2004. Pharmacy Benefits and the Use of Drugs by the Chronically Ill. Journal of the American Medical Association 291(19): 2344-2350.
10. HHS News. 2005. HHS takes major step to prescription drug benefit. Jan. 21.
11. Huskamp, H., P. Deverka, and A. Epstein, et al. 2003. The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending. New England Journal of Medicine 349(23): 2224-2232.
12. Huskamp, H., M. Rosenthal, R. Frank, and J. Newhouse. 2000. The Medicare Prescription Drug Benefit: How Will the Game Be Played? Health Affairs 19(2): 8-23.
13. Keenan, P. S., M. Beeuwkes Buntin, T. McGuire, and J. Newhouse. 2001. The Prevalence of Formal Risk Adjustment in Health Plan Purchasing. Inquiry 38(3): 245-259.
14. Lamers, L. 2001. Health-Based Risk Adjustment: Is Inpatient and Outpatient Diagnostic Information Sufficient? Inquiry 38(4): 423-431.
15. McClellan, M., I. Spatz, and S. Carney. 2000. Designing A Medicare Prescription Drug Benefit: Issues, Obstacles, and Opportunities. Health Affairs 19(2): 26-41.
16. Nagel, R. 1995. Unraveling in Guessing Games: An Experimental Study. American Economic Review 85(5): 1313-1326.
17. Newhouse, J. 2004. How Much Should Medicare Pay For Drugs? Health Affairs 23(1): 89-102.
18. Pauly, M., and Y. Zeng. 2004. Adverse Selection and the Challenge to Stand-Alone Prescription Drug Insurance. Frontiers in Health Policy Research 7: 55-74.
19. Pear, R. 2005. Medicare Insists on Wider Choice in Drug Benefits. New York Times June 15:A1.
20. Zhao, Y., A. Ash, and R. Ellis, et al. 2005. Predicting Pharmacy Costs and Other Medical Costs Using Diagnoses and Drug Claims. Medical Care 4: 34-43.